The company said revenue for the fiscal Q3 quarter ended July 31, 2024 rose 8% from a year earlier to $1,002.8 million. CooperVision revenue was $675.6 million, up 7%, and CooperSurgical revenue was $327.2 million, up 9%.

1. 01

   The company said revenue for the fiscal Q3 quarter ended July 31, 2024 rose 8% from a year earlier to $1,002.8 million. CooperVision revenue was $675.6 million, up 7%, and CooperSurgical revenue was $327.2 million, up 9%.

2. 02

   The Cooper Companies said GAAP diluted earnings per share for Q3 were $0.52, up $0.09 from a year earlier, and non-GAAP diluted EPS was $0.96, up $0.12. It said GAAP net income was $104.7 million.

3. 03

   The company said its GAAP operating margin for Q3 was 19% (16% in the same quarter last year), and its non-GAAP operating margin was 26% (24% a year earlier). Free cash flow, calculated as cash provided by operating activities of $207.5 million less capital expenditures of $89.0 million, was $118.5 million.

4. 04

   The Cooper Companies said it raised its fiscal 2024 outlook. It expects full-year total revenue of $3,892 to $3,913 million (organic growth of 8% to 8.5%) and non-GAAP diluted EPS of $3.64 to $3.67.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.